PRESCRIPTION PATTERN OF CLINICAL USE AND SAFETY PROFILE OF LINEZOLID IN TERTIARY CARE TEACHING INSTITUTE : AN OBSERVATIONAL STUDY
Background: Linezolid acts by inhibiting protein synthesis and the mode of action does not lead to cross resistance with other antimicrobials. With increasing infection due to VRE, linezolid is the best option available. Reports of resistance to linezolid along with the characterization of mechanism of resistance have been documented in Enterococcus sp., Staphylococcus sp. and MRS. Studies from India, has shaown all Staphylococcus sp. and Enterococcus sp. remain linezolid sensitive except for occasional case reports. The 85% of reported adverse events was mild-to-moderate in intensity. Linezolid over usage and irrational clinical use may leads to drug resistance. Generally linezolid is kept as a reserve drug for multidrug resistant infections. The objective of Aim & Objectives: this study is to find out the prescription pattern of Linezolid for a period of six months in various departments and the second objective is to observe the sequencial adverse drug reactions of linezolid of Malabar medical college and research center. In this retrospective s Methodology: tudy, the pattern of linezolid use during 6 month period in patients admitted to different wards of Malabar medical college and research center was analysed. (Ethical Code:). A standard protocol on linezolid indications, dosing and monitoring was designed based on Sanford guide for antimicrobial therapy Results: Overall, the patient population consisted of different groups with varying ages, weights and renal functionsA significant proportion of patients had some degree of kidney impairment, and many were treated as inpatients, including treatment in the ICU. The most common infections treated with linezolid were skin and soft tissue infections (SSTI), followed by primary bacteremia, secondary bacteremia, and bone and joint infections. In conclusion, linezolid remains an important therapeutic option for infections caused b Conclusion: y resistant pathogens, but its use should be guided by careful consideration of the patient's clinical condition, the specific infection, and the susceptibility of the causative microorganism.
Authors
- Paul Mathai (ORCID: https://orcid.org/0000-0002-9965-5263)
- Anu Chandran
Institutions
- Institute of Medical Sciences (IN)
Publication Details
- Journal
- INDIAN JOURNAL OF APPLIED RESEARCH
- Published
- 2025-03-01
- DOI
- https://doi.org/10.36106/ijar/6502542
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00